サクビトリル・バルサルタン
↑ “Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap”. JACC Heart Fail 5 (6): 460–463. (June 2017). doi:10.1016/j.jchf.2017.03.007. PMID 28571599.
↑ “Richard Lehman's journal review—8 September 2014”. The BMJ (2014年9月8日). 2019年5月20日閲覧。
↑ “Do limitations in the design of PARADIGM-HF justify the slow real world uptake of sacubitril/valsartan (Entresto)?”. Cardiovascular Drugs and Therapy 32 (6): 633–5. (2018). doi:10.1007/s10557-018-6830-x. PMID 30232657. https://static1.squarespace.com/static/55550f38e4b0884d8d80118e/t/5bd915c4032be422670e74ef/1540953541892/2018.+Do+Limitations+in+the+desing+of+PARADIGM-HF+justify+the+slow+real+world+uptake+of+SacubitrilValsartan+Entresto.pdf.